Table 2.
Distribution frequency of high-mobility group box 1 (HMGB1) genotypes of patients with lung adenocarcinoma and multiple logistic regression analysis of epidermal growth factor receptor mutations associated with the cigarette smoking status.
| All cases (N=280) | Non-smokers (N=181) | Smokers (N=99) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SNP genotype | Wild type (N=111) | Mutation type (N=169) | AOR (95% CI) | Wild type (N=50) | Mutation type (N=131) | AOR (95% CI) | Wild type (N=61) | Mutation type (N=38) | AOR (95% CI) |
| rs1412125 | |||||||||
| TT | 59 (53.2%) | 89 (52.7%) | 1.00 | 28 (56.0%) | 67 (51.1%) | 1.00 | 31 (50.8%) | 22 (57.9%) | 1.00 |
| TC | 43 (38.7%) | 66 (39.1%) | 0.82 (0.44~1.54) | 20 (40.0%) | 53 (40.5%) | 0.76 (0.29~1.95) | 23 (37.7%) | 13 (34.2%) | 0.82 (0.21~3.18) |
| CC | 9 (8.1%) | 14 (8.2%) | 0.95 (0.27~3.32) | 2 (4.0%) | 11 (8.4%) | 3.55 (0.28~45.12) | 7 (11.5%) | 3 (7.9%) | 0.23 (0.02~3.00) |
| TC+CC | 52 (46.8%) | 80 (47.3%) | 0.84 (0.46~1.54) | 22 (44.0%) | 64 (48.9%) | 0.89 (0.35~2.22) | 30 (49.2%) | 16 (42.1%) | 0.64 (0.18~2.29) |
| rs2249825 | |||||||||
| CC | 74 (66.7%) | 127 (75.1%) | 1.00 | 39 (78.0%) | 95 (72.5%) | 1.00 | 35 (57.4%) | 32 (84.2%) | 1.00 |
| CG | 34 (30.6%) | 37 (21.9%) | 0.55 (0.27~1.10) | 10 (20.0%) | 33 (25.2%) | 1.19 (0.41~3.50) | 24 (39.3%) | 4 (10.5%) | 0.07 (0.01~0.74)* |
| GG | 3 (2.7%) | 5 (3.0%) | 2.06 (0.36~11.87) | 1 (2.0%) | 3 (2.3%) | 1.52 (0.09~27.00) | 2 (3.3%) | 2 (5.3%) | 2.21 (0.09~57.15) |
| CG+GG | 37 (33.3%) | 42 (24.9%) | 0.63 (0.32~1.23) | 11 (22.0%) | 36 (27.5%) | 1.22 (0.43~3.45) | 26 (42.6%) | 6 (15.8%) | 0.16 (0.03~1.02) |
| rs1045411 | |||||||||
| CC | 62 (55.9%) | 103 (60.9%) | 1.00 | 33 (66.0%) | 76 (58.0%) | 1.00 | 29 (47.5%) | 27 (71.1%) | 1.00 |
| CT | 41 (36.9%) | 56 (33.1%) | 0.80 (0.42~1.52) | 14 (28.0%) | 48 (36.6%) | 2.23 (0.84~5.92) | 27 (44.3%) | 8 (21.1%) | 0.12 (0.02~0.69)* |
| TT | 8 (7.2%) | 10 (6.0%) | 1.12 (0.33~3.81) | 3 (6.0%) | 7 (5.4%) | 0.76 (0.13~4.48) | 5 (8.2%) | 3 (7.9%) | 0.71 (0.06-8.89) |
| CT+TT | 49 (44.1%) | 66 (39.1%) | 0.84 (0.46~1.55) | 17 (34.0%) | 55 (42.0%) | 1.83 (0.75~4.47) | 32 (52.5%) | 11 (28.9%) | 0.38 (0.15~0.96)* |
| rs1360485 | |||||||||
| TT | 60 (54.1%) | 94 (55.6%) | 1.00 | 32 (64.0%) | 69 (52.7%) | 1.00 | 28 (45.9%) | 25 (65.8%) | 1.00 |
| TC | 40 (36.0%) | 64 (37.9%) | 1.05 (0.55~1.97) | 15 (30.0%) | 55 (42.0%) | 3.07 (1.12~8.38*) | 25 (41.0%) | 9 (23.7%) | 0.12 (0.02~0.72)* |
| CC | 11 (9.9%) | 11 (6.5%) | 0.96 (0.29~3.16) | 3 (6.0%) | 7 (5.3%) | 0.89 (0.15~5.34) | 8 (13.1%) | 4 (10.5%) | 0.51 (0.05~5.11) |
| TC+CC | 51 (45.9%) | 75 (44.4%) | 1.03 (0.56~1.89) | 18 (36.0%) | 62 (47.3%) | 2.47 (0.98~6.20) | 33 (54.1%) | 13 (34.2%) | 0.18 (0.04~0.86)* |
The adjusted odds ratios (AORs) with 95% confidence intervals (CIs) were estimated by multiple logistic regression models after controlling for age and gender.
Note: Bold text indicates a significant association with p value of <0.05.
Abbreviations: SNP, single-nucleotide polymorphism.